Skip to main content
SpringerLink
Log in

Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases

  • Chapter
  • First Online:
Book cover Myasthenia Gravis and Related Disorders

Part of the book series: Current Clinical Neurology ((CCNEU))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

REFERENCES

  1. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973;180:871–72.

    Article  PubMed  CAS  Google Scholar 

  2. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973;182:293–295.

    Article  PubMed  CAS  Google Scholar 

  3. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054–9.

    PubMed  CAS  Google Scholar 

  4. Toyka, KV, Drachman, DB, Griffin DE, Pestronk A, Winkelstein JA, Fischbeck KH, Kao I. Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N Eng J Med 1977; 296:125–131.

    Article  CAS  Google Scholar 

  5. Pinching AJ, Peters DK, Newsom-Davis JN. Remission of myasthenia gravis following plasma exchange. Lancet 1976;2:1373–1376.

    Article  PubMed  CAS  Google Scholar 

  6. Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to a mouse. J Physiol (Lond) 1983;344: 335–345.

    CAS  Google Scholar 

  7. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995;38:714–722.

    Article  PubMed  CAS  Google Scholar 

  8. Mossman S, Vincent A, Newsom-Davis J. Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between antibody bound, acetylcholine receptor loss and transmission defect. J Neurol Sci 1988;84:15–28.

    Article  PubMed  CAS  Google Scholar 

  9. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579–601.

    Article  PubMed  CAS  Google Scholar 

  10. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetycholine receptor in myasthenia gravis: investigated by plasma exchange. Neurology 1978;28:266–272.

    PubMed  CAS  Google Scholar 

  11. Dau, PC. Plasmpheresis therapy in mysthenia gravis. Muscle Nerve 1980;3:468–482.

    Article  PubMed  CAS  Google Scholar 

  12. Oosterhuis HJGH, Limburg PC, Hummel-Tappel E. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 1983;58:371–385.

    Article  PubMed  CAS  Google Scholar 

  13. Tzartos SJ, Loutrari HV, Tang F, et al. Main immunogenic region of torpedo electroplax and human muscle acetylcholine receptor: localization and microheterogeneity revealed by the use of synthetic peptides. J Neurochem 1990;54:51–61.

    Article  PubMed  CAS  Google Scholar 

  14. Lennon VA, Seybold ME, Lindstrom JM, Cochrane C, Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978;147:973–983.

    Article  PubMed  CAS  Google Scholar 

  15. Corey AL, Richman DP, Agius MA, Wollmann RL. Refractoriness to a second episode of experimental myasthenia gravis: correlation with AChR concentration and morphologic appearance of the postsynaptic membrane. J Immunol 1987;138:3269–3275.

    PubMed  CAS  Google Scholar 

  16. Gomez CM, Richman DP. Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetycholine receptor: biochemical and electrophysiological criteria. J Immunol 1987;139:73–76.

    PubMed  CAS  Google Scholar 

  17. Maselli RA, Richman DP, Wollmann RL. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology 1991;41:1497–1504.

    PubMed  CAS  Google Scholar 

  18. Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the alpha bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci (USA) 1983;80:4089–4093.

    Article  CAS  Google Scholar 

  19. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982;307:769–75.

    Article  PubMed  CAS  Google Scholar 

  20. Dupont BL, Twaddle GM, Richman DP. Suppression of passive transfer acute experimental myasthenia by F(Ab’)2 fragments. J Neuroimmunol 1987;16:47 Abstract.

    Article  Google Scholar 

  21. Howard FM, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block or modulate human acetylcholine receptors in myasthenia gravis. Ann NY Acad Sci 1987;505:526–538.

    Article  PubMed  Google Scholar 

  22. Vincent A, Newsom-Davis J. Anti-acetycholine receptor antibodies. J Neurol Neurosurg Psychiatry. 1980;43:590–600.

    Article  PubMed  CAS  Google Scholar 

  23. Maselli RA, Ellis W, Mandler RN, Sheikh F, Senton G, Knox S, Salari-Namin H, Agius M, Wollmann RL, Richman DP. Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve 1997;20:1284–1295.

    Article  PubMed  CAS  Google Scholar 

  24. Kaminski, HJ. Acetylcholine receptor epitopes in ocular myasthenia. Ann NY Acad Sci. 1998;841:309–19.

    Article  PubMed  CAS  Google Scholar 

  25. Lennon VA. Serological diagnosis of myasthenia gravis and the Lambert Eaton Myasthenic syndrome. In Lisak RP, ed. Handbook of Myasthenia Gravis and Myasthenic Syndromes. Marcel Dekker, Inc. New York. 1994: 149–164.

    Google Scholar 

  26. Lang B, Richardson G, Rees J, Vincent A, Newsom-Davis J. Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. J Neuroimmunol 1988;19:141–8.

    Article  PubMed  CAS  Google Scholar 

  27. Bufler J, Pitz R, Czep M, Wick M, Franke C. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 1998;43:458–64.

    Article  PubMed  CAS  Google Scholar 

  28. Murakami M, Hosoi Y, Araki O, Morimura T, Imamura M, Ogiwara T, Mizuma H, Mori M. Expression of thyrotropin receptors in rat thymus. Life Sci 2001; 68:2781–7.

    Article  PubMed  CAS  Google Scholar 

  29. Aarli J. Myasthenia gravis and thymoma. In Lisak RP, ed Handbook of Myasthenia Gravis and Myasthenic Syndromes. Marcel Dekker, Inc. New York. 1994:207–224.

    Google Scholar 

  30. Lefvert AK, Bergstrom K, Mattel G, Osterman PO, Pirksanen R. Determination of acetycholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394–403.

    Article  PubMed  CAS  Google Scholar 

  31. Strauss AJ, Seegal BC, Hsu JC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol (NY) 1960;195:184–191.

    Google Scholar 

  32. Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82:284–288.

    Article  PubMed  CAS  Google Scholar 

  33. Skeie GO, Lunde PK, Sejersted OM, Mygland A, Aarli JA, Gilhus NE. Autoimmunity against the ryanodine receptor in myasthenia gravis. Acta Physiol Scand 2001;171:379–384.

    Article  PubMed  CAS  Google Scholar 

  34. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000;247:369–375.

    CAS  Google Scholar 

  35. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000;57:1596–600.

    Article  PubMed  CAS  Google Scholar 

  36. Romi F. Muscle autoantibodies in myasthenia gravis (MG): clinical, immunological and therapeutic implications. 2001. Thesis, University of Bergen.

    Google Scholar 

  37. Mygland A, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, Gilhus NE, Aarli JA. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol 2000;57:527–531

    Article  PubMed  CAS  Google Scholar 

  38. Lee E-K, Maselli RA, Ellis WG, Agius MA. Morvan’s fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psych 1998;65:857–862.

    Article  CAS  Google Scholar 

  39. Agius MA, Zhu S, Kirvan CA, Schafer A, Lin MY, Fairclough RH, Oger JJ-F, Aziz T, Aarli JA. Rapsyn antibodies in myasthenia gravis. Ann NY Acad Sci 841:516–524.

    Google Scholar 

  40. Hagiwara H, Enomoto-Nakatani S, Sakai K, Ugawa Y, Kusunoki S, Kanazawa IJ. Stiff-person syndrome associated with invasive thymoma: a case report. Neurol Sci 2001;193:59–62

    Article  CAS  Google Scholar 

  41. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001;57:1579–82.

    PubMed  CAS  Google Scholar 

  42. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986;1:116–9.

    Article  PubMed  CAS  Google Scholar 

  43. Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, Tonali P. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord 1996;6:155–61.

    Article  PubMed  CAS  Google Scholar 

  44. Blaes F, Beeson D, Plested P, Lang B, Vincent A. IgG from “seronegative” myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Ann Neurol 2000;47:504–510.

    Article  PubMed  CAS  Google Scholar 

  45. Yamamoto T, Vincent A. Ciulla TA, Lang B, Johnston I. Newsom-Davis J. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann Neurol 1991;30:550–557.

    Article  PubMed  CAS  Google Scholar 

  46. Plested CP, Newsom-Davis J, Vincent A. Seronegative myasthenia plasmas and non-IgG fractions transiently inhibit nAChR function. Ann NY Acad Sci 1998;841:501–4.

    Article  PubMed  CAS  Google Scholar 

  47. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365–368.

    Article  PubMed  CAS  Google Scholar 

  48. Vincent A, Leite MI, Farrugia ME, Jacob S, Viegas S, Shiraishi H, Benveniste O, Morgan BP, Hilton-Jones D, Newsom-Davis J, Beeson D, Willcox N. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann NY Acad Sci. 2008;1132:84–92.

    Google Scholar 

  49. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgGl antibodies to acetylcholine receptors in “seronegative” MG. Brain 2008;131:1940–1952.

    Google Scholar 

  50. Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5:S21–5.

    PubMed  CAS  Google Scholar 

  51. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984;34: 480–485.

    PubMed  CAS  Google Scholar 

  52. Fukunaga H, Engel AG, Osame M, Lambert EH. Paucity and disorganization of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5:686–697.

    Article  Google Scholar 

  53. Fukuoka T, Engel AG, Lang B, Newsom-Davis J, Prior C, Wray DW. Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones. Ann Neurol 1987;22:139–199.

    Google Scholar 

  54. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 1985;317:737–9.

    Article  PubMed  CAS  Google Scholar 

  55. Johnston I, Lang B, Leys K, Newsom-Davis J. Heterogeneity of calcium channel autoantibodies detected using a small cell lung cancer line derived from a Lambert-Eaton syndrome patient. Neurology 1994;44:334–338.

    PubMed  CAS  Google Scholar 

  56. Viglione MP, O’Shaughnessy TJ, Kim Y. Inhibition of calcium currents and exocytosis by Lambert-Eaton myasthenic syndrome antibodies in human lung cancer cells. J Physiol Lond 1995;488:303–17.

    PubMed  CAS  Google Scholar 

  57. Protti DA, Reisen R, MacKinley TA, Uchitel OD. Calcium channel blockers and transmitter release at the normal human neuromuscular junction. Neurology 1996;46:1391–1396.

    PubMed  CAS  Google Scholar 

  58. Pinto A, Gillard S, Moss F, Whyte K, Brust P, Williams M, Stauderman K, Harpold M, Lang B, Newsom-Davis J, Bleakman D, Lodge D, Boot J. Human autoantibodies specific for α1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci 1998;95:8328–8333.

    Article  PubMed  CAS  Google Scholar 

  59. Espiritu DJ, Watkins M, Dia-Monje V, Cartier GE, Cruz LJ, Olivera BM. Venomous cone snails: molecular phylogeny and the generation of toxin diversity. Toxicon 2001;39:1899–916.

    Article  PubMed  CAS  Google Scholar 

  60. Sher E, Comola M, Nemni R, Canal N, Clementi F. Calcium channel autoantibody and non-small-cell lung cancer in patients with Lambert-Eaton syndrome. Lancet 1990;335:413.

    Article  PubMed  CAS  Google Scholar 

  61. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85–87.

    Article  PubMed  CAS  Google Scholar 

  62. Lennon VA, Kryzer TJ, Greismann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert E. Calcium channel antibodies in the Lambert-Eaton myasthenic syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467–74.

    Article  PubMed  CAS  Google Scholar 

  63. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35–42.

    Article  PubMed  CAS  Google Scholar 

  64. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium channel antibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678–683.

    PubMed  CAS  Google Scholar 

  65. Mason WP, Graus F, Lang B, Honnorat J, Delatrre J-Y, Vallderiola F, Antoine C, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J. Paraneoplastic cerebellar degeneration and small-cell carcinoma. Brain 1997;120:1279–1300.

    Article  PubMed  Google Scholar 

  66. Trivedi R, Mundanthanan G, Amyes L, Lang B, Vincent A. Which antibodies are worth testing in subacute cerebellar ataxia? Lancet 2000;356:565–566.

    Article  PubMed  CAS  Google Scholar 

  67. Sinha S, Newsom-Davis J, Mills K, et al. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 1991;338, 75–77.

    Article  PubMed  CAS  Google Scholar 

  68. Sonoda, Y., Arimura, K., Kurono, A. et al. Serum of Isaacs' syndrome suppresses potassium channels in PC-12 cell lines. Muscle Nerve 1996;19:1439–1446.

    Article  PubMed  CAS  Google Scholar 

  69. Arimura K, Watanabe O, Kitajima I. et al. Antibodies to potassium channels of PC12 in serum of Isaacs' syndrome: Western blot and immunohistochemical studies. Muscle Nerve 1997;20:299–305.

    Article  PubMed  CAS  Google Scholar 

  70. Nagado T, Arimura K, Sonoda Y, et al. Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 1999;122:2057–2066.

    Article  PubMed  Google Scholar 

  71. Harvey AL, Rowan EG, Vatanpour H, Fatehi M, Castaneda O, Karlsson E. Potassium channel toxins and transmitter release. Ann NY Acad Sci 1994;710:1–10.

    Article  PubMed  CAS  Google Scholar 

  72. Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997;41:238–46.

    Article  PubMed  CAS  Google Scholar 

  73. Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M, Vincent Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50:73–8.

    Article  PubMed  CAS  Google Scholar 

  74. Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, Baruzzi A, Carey T, Gambetti P, Lugaresi E, Montagna P. Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001;124:2417–2426.

    Article  PubMed  CAS  Google Scholar 

  75. Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999;131:522–30.

    PubMed  CAS  Google Scholar 

  76. Dalakas, MC, Li M, Fujii M, Jacobowitz DM. Quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 2001;57:780–784.

    PubMed  CAS  Google Scholar 

  77. Sohnlein P, Muller M, Syren K, Hartmann U, Bohm BO, Meinck HM, Knip M, Akerblom HK, Richter W. Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes. The Childhood Diabetes in Finland Study Group. Diabetologia 2000;43:210–7.

    Article  PubMed  CAS  Google Scholar 

  78. Schmierer K, Valdueza JM, Bender A, DeCamilli P, David C, Solimena M, Zschenderlein R. Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology 1998;51:250–2.

    PubMed  CAS  Google Scholar 

  79. Butler MH, Hayashi A, Ohkoshi N, Villmann C, Becker CM, Feng G, De Camilli P, Solimena M. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000 May;26(2):307–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of California, Davis, CA

    Mark A. Agius & David P. Richman

  2. Institute of Molecular Medicine, John Radcliffe Hospital and Oxford University, Oxford, UK

    Angela Vincent

Authors
  1. Mark A. Agius
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Richman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Vincent
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Agius, M.A., Richman, D.P., Vincent, A. (2009). Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases. In: Myasthenia Gravis and Related Disorders. Current Clinical Neurology. Humana Press. https://doi.org/10.1007/978-1-59745-156-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-156-7_9

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-852-2

  • Online ISBN: 978-1-59745-156-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation